BMC Cancer · 2021 · 28 citations · 21 references
MedicineOncologyPharmacologyCancer ControlCancer EpidemiologyChemotherapyAdverse Effects Of ChemotherapyLung Cancer PharmacotherapyDelayed Chemotherapy-induced NauseaDelayed Chemotherapy-induced VomitingLung Cancer EpidemiologyNausea And Vomiting ControlNausea In Advanced CancerPropensity Score Adjustment
BACKGROUND: Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compare the incidence of CINV between lung cancer patients undergoing carboplatin plus pemetrexed (CBDCA+PEM) and those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy. METHODS: Pooled data of 240 patients from two prospective observational studies were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify risk factors for nausea and vomiting following chemotherapy. RESULTS: Delayed nausea was significantly more common in patients treated with CBDCA+PEM than in those treated with CBDCA+PTX (51.1% vs. 36.2%, P = 0.04), but the incidence of vomiting did not significantly differ between the two groups (23.4% vs. 14.9%, P = 0.14). The occurrence of CINV peaked on day 4 in the CBDCA+PTX group and on day 5 in the CBDCA+PEM group. Multivariate analysis showed that female sex, younger age, and CBDCA+PEM regimen were independent risk factors for delayed nausea, while female sex was an independent risk factor for delayed vomiting. CONCLUSIONS: The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM.
21
Al B. Benson, Thomas A. Abrams, Edgar Ben‐Josef et al. · Journal of the National Comprehensive Cancer Network · 2009 · 2.3K citations · Full text
Yuichiro Ohe, Yasuo Ohashi, Kaoru Kubota et al. · Annals of Oncology · 2006 · 637 citations
Medicine, Oncology, Pharmacology +17
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy et al. · New England Journal of Medicine · 2016 · 450 citations · Full text
Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 235 citations